Natalia Sholoiko

Mrs. Natalia Sholoiko

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
NSNatalia Sholoiko
Natalia Sholoiko
AGA. O. Gonchar
A. O. Gonchar
Cardiovascular disease is the most common cause of death and disability worldwide. There are more than 12 million patients with hypertension in Ukraine. Timely prescription of medicines patients with AH in accordance with current clinical guidelines significantly improves the quality of life and survival of patients. The purpose of the study was to conduct a comparative analysis of the international and domestic range of modern medicines for the treatment of hypertension according to INN and ATC-classification and to investigate the status of their registration and inclusion in the reimbursement lists in Ukraine in order to determine the potential physical availability of drugs for the treatment of hypertension. An analysis of the domestic regulatory framework showed that international CG for the treatment of hypertension and national CPs can be used in Ukraine. The content analysis of the CG showed that international CG include classes of medicines for initial and maintenance therapy of hypertension: ACE inhibitors, ARBs, diuretics (thiazide and thiazide-like), calcium antagonists and beta-blockers, while preference is given to combinations of these drugs due to better adherence patients for treatment. It was found that according to the ATC classification, 41 ACE inhibitors and their combinations are represented on the international pharmaceutical market for the treatment of hypertension; of which 16 are single-component drugs, 25 are combined; ARB II and their combinations ‒ 32, single-component 10, combinations ‒ 22; calcium channel blockers and their combinations ‒ 21, single-component ‒ 18, combinations ‒ 2, thiazide diuretics ‒ 10, thiazide-like diuretics ‒ 11. An analysis of the status of registration in Ukraine according to certain INN and ATC classification showed that 56 drugs were registered, which is 48.69% of the possible 115 (drugs and ACE inhibitors and their combinations 22 (53.65%), ARBs II and their combinations 21 (65.63%); CCBs and their combinations ‒ 8 (38.10%); thiazide diuretics ‒ 1 (10%), thiazide-like diuretics ‒ 3 (27.27%)).

31 August 2022 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
AGAnton Gonchar
Anton Gonchar
NSNatalia Sholoiko
Natalia Sholoiko
The aim was to conduct a retrospective consumption analysis of 4 groups of single pill combinations for hypertension treatment and identify potential candidates for future inclusion in the reimbursement list in Ukraine, based on retrospective consumption patterns. Materials and methods: The objects of the study were retail sales data in pharmaceutical market in Ukraine of four groups of single pill combinations used for arterial hypertension treatment. Data was provided by the marker research system “Pharmstandard” of the company of “Morion”. Analytic-comparative, systematic, logical, and mathematical-statistical methods were used. Results: Single pill combinations of ACE inhibitors with diuretics were the most consumed among other combinations on 2018-2020. Retrospective evaluation of consumption patterns in period of 2018-2020 showed that combinations of captopril and hydrochlorothiazide (HCTD) 50 mg/25 mg, enalapril and HCTD 10 mg/25 mg, lisinopril and HCTD 10 mg/12.5 mg were the most consumed. Among ARB and diuretics combinations valsartan and HTCD (160 mg/12.5 mg and 80 mg/12.5 mg) and losartan and HTCD (50 mg /12.5 mg) were the most consumed among ARB and diuretics combinations. Within ACE inhibitors and calcium channel blockers (CCB) combinations the most consumed were lisinopril/amlodipine 10 mg/5 mg and a perindopril arginine/amlodipine 5 mg/5 mg. Valsartan and amlodipine holds the majority among ARC and CCB combinations, consumed in period of 2018-2020. Conclusion: Apart from the single pill combinations, enlisted in the WHO Essential medicines list, eight more single pill combination were identified, based on retrospective consumption patterns, as potential candidates for further inclusion in the reimbursement list in Ukraine

27 October 2023 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ІНІ. В. Ніженковська
І. В. Ніженковська
МБМ. М. Бабенко
М. М. Бабенко
ЛГЛ. О. Гала
Л. О. Гала
NSNatalia Sholoiko
Natalia Sholoiko
НДН. О. Дацюк
Н. О. Дацюк
INI. V. Nizhenkovska
I. V. Nizhenkovska
The price of medicines is an important factor in ensuring accessibility for the population in the healthcare. Ukraine actively implements pricing policies in the healthcare in accordance with the recommendations of the World Health Organization (WHO). WHO recommendations aim to achieve two important objectives. First, they seek to ensure the availability of effective medicines for the population so that every patient has the opportunity to receive necessary treatment. Second, it is to create conditions for pharmaceutical companies to have incentives to continue their innovative activities in the field of medicine. The purpose of the research is to analyze and evaluate pricing policies that ensure the accessibility of medicines for the Ukrainian population through state budget funding and their compliance with WHO recommendations. It has been established that in Ukraine, there are several directions aimed at ensuring the population's accessibility to medicines through state budget funding: the purchase of medicines within the National Essential Medicine List, the «Affordable Medicines» program, centralized procurement of medicines and the purchase of innovative medicines through Managed Entry Agreements. Pricing for medicines under various programs is carried out using different approaches. An analysis of the legislative environment regulating medicine pricing in Ukraine in accordance with WHO-recommended pricing policies has revealed that several pricing policies are functioning at a satisfactory level. These include external and internal reference pricing, mark-up regulation, cost-based pricing, as well as tax exemptions or reductions for medicines. However, there are policies that require further development and improvement. These include promoting price transparency, conducting tenders and negotiations, consolidating procurement, promoting the use of generics and biosimilars with guaranteed quality, as well as introducing cost-plus pricing to determine medicine prices. Thus, standardization of the lists of medicines and pricing approaches is one of the most important tasks on the path to European integration. Monitoring market prices with control over their compliance is a necessary step to improve the population's access to effective medicines.

31 August 2022 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
MFMaryna Fedotova
Maryna Fedotova
HPHanna Panfilova
Hanna Panfilova
LHLiliia Hala
Liliia Hala
ALAlla Lebedyn
Alla Lebedyn
LSLiusine Simonian
Liusine Simonian
MVMariia Velia
Mariia Velia
The aim: to assess the state of pharmaceutical provision of patients with dementia in Alzheimer's disease in Ukraine in accordance with international recommendations. Materials and methods. In our studies, we used data from international guidelines, clinical protocols that regulate the organization of medical and pharmaceutical care for these patients in the USA, Australia, Japan, Germany, Great Britain, Finland, India, Kazakhstan, and Ukraine. The actual state of pharmaceutical provision of these patients in Ukraine was studied using a depersonalized database of medical prescriptions, which operates based on a number of specialized healthcare institutions. In addition, data from the Morion information search system were used. We used general theoretical (historical, formal, graphic, hypothetical-deductive, etc.) and applied (clinical-economic, organizational-economic, mathematical-statistical, etc.) research methods. Results. It has been established that a consolidated opinion has been formed in the world scientific community regarding the possibility of effective use in the pathogenetic treatment of patients with dementia in Alzheimer's disease of drugs from the groups N06DA Acetylcholinesterase inhibitors and N06DX-Other drugs for use in case of dementia. Thus, the pharmaceutical component of international recommendations, clinical protocols for the treatment of patients with dementia in Alzheimer's disease contains four drugs used in pathogenetic therapy. These are N06DA02 Donepezil, N06DA03 Rivastigmine, N06DA04 Galantamine and N06DX01 Memantine. It has been reported that all the above drugs are included in the domestic clinical protocol for the treatment of patients with dementia in Alzheimer's disease, the State Drug Formulary (with the exception of N06DA03 Rivastigmine), and the State Drug Registry. At the same time, all of them were absent from the National List of Essential Drugs, which has an important socio-economic and medical-pharmaceutical significance in the health care system. It was found that patients (200 people) received 2487 prescriptions (100.0 %), among which 9.41 % (234 prescriptions) were drugs used in pathogenetic treatment. There is a highly disproportionate nature of the distribution of prescriptions and consumption by international generic names of drugs. Thus, drugs N06DX01 Memantine accounted for 80.41 % (188 prescriptions) of all prescriptions in the group N06D Drugs for use in dementia, and the consumption rate was UAH 84420.20, which accounted for 91.48 % of the amount of expenses directed to patients with carrying out pathogenetic treatment. Significant dominance of drugs N06DX01 Memantine in the structure of prescriptions and consumption indicates the presence of severe, advanced forms of dementia in patients. This fact once again emphasizes the need for early detection and treatment of cognitive impairment, primarily for the rational use of limited health care resources. We have found that there are no prescriptions for N06D A04 Galantamine preparations, which are recommended by the relevant international recommendations in different countries of the world, as well as by the domestic clinical protocol for the pathogenetic treatment of mild and moderate forms of Alzheimer's disease. At the same time, N06DA05 Ipidacrine preparations were used in the treatment of domestic patients, which are not presented in the pharmaceutical component of international recommendations and protocols governing the pathogenetic treatment of the above-mentioned groups of neuropsychiatric patients. Conclusions. The peculiarities of the formation of the pharmaceutical component in the organization of the treatment process of patients with dementia in Alzheimer's disease in Ukraine, established by us, allow further research on the development of rational ways of resource provision of neuropsychiatric patients

30 August 2025 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
AGAnton Gonchar
Anton Gonchar
NSNatalia Sholoiko
Natalia Sholoiko
KKKostyantyn Kosyachenko
Kostyantyn Kosyachenko
OKOleksandr Komarida
Oleksandr Komarida
The aim to conduct a retrospective study of the consumption of 4 groups of two-component combined drugs for the treatment of arterial hypertension and to determine the structure of their consumption by the number of tablets, , taking into account active substances and their doses, to further formulate proposals to improve the provision of medicines to consumers, in particular through the state reimbursement program "Affordable Medicines". Materials and methods: The objects of the study were retail sales data for the period 2020-2024 on the pharmaceutical market of Ukraine for four groups of combined antihypertensive drugs. The data was provided by the Ukrainian pharmaceutical market research system "Pharmstandard" of the Morion company. The study used statistical and mathematical methods, as well as content analysis, comparative, logical, and systemic analysis, and data generalization. Results: showed that combined drugs of ACE inhibitors and diuretics are the most consumed among all two-component combined drugs for the treatment of hypertension in Ukraine in 2020–2023. By median share of consumption, the following fixed-dose combinations of captopril/HCTZ (50 mg/25 mg) median 29.04%; enalapril/HCTZ (10 mg/25 mg) median 11.74%; lisinopril/HCTZ (10 mg/12.5 mg) median 11.64% and perindopril tertbutylamine with indapamide (8mg/2.5mg) –11.42% among ACE inhibitors and diuretics combinations; valsartan/HCTZ (160 mg/12.5 mg (median 40.02%); and 80 mg/12.5 mg (median 29.07%); losartan/HCTZ (50mg/12.5mg) median 11.30% among ARB and diuretic combinations; lisinopril/amlodipine (5mg/5mg) median 15.25%; and (10mg/5mg) median 11.98% perindopril arginine and amlodipine (5mg/5mg) median 13.77%; and perindopril tertbutylamine and amlodipine (4mg/5mg) median 11.08%; of all combinations of ACE inhibitors and CCBs; ; and valsartan/amlodipine, in all three available doses (160mg/5mg, 80mg/5mg and 160mg/10mg) median 43.71%; 31.36% and 20.32% respectively, among the combinations of ARBs and CCBs had the highest median consumption share in each respective group of combination drugs and were used by patients for the treatment of hypertension in Ukraine in 2020-2024. Conclusion: Retail sales results showed that combined drugs of ACE inhibitors and diuretics, as well as combined drugs of ARBs and diuretics, are the most consumed among all two-component combined drugs for the treatment of hypertension in Ukraine in 2020-2023. Further analysis of the structure of consumption of fixed-dose combinations, considering active substances and their doses, made it possible to determine within each study group those fixed doses that have the highest median consumption share values over four years. It is regarding them that we propose conducting further clinical and economic studies on their use in the context of discussing the issue of expanding the list of combined drugs for the treatment of hypertension that are subject to reimbursement in Ukraine

29 December 2022 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
AGA. O. Gonchar
A. O. Gonchar
NSNatalia Sholoiko
Natalia Sholoiko
ОКО. О. Комаріда
О. О. Комаріда
Cardiovascular diseases (CVD), in particular arterial hypertension (AH), are the main causes of morbidity and mortality, Ukraine is on the 1st place in Europe for mortality from these diseases. Modern clinical guidelines emphasize the use of combined antihypertensive drugs, and improving the accessibility of these medicines for Ukrainian patients with hypertension is relevant. In Ukraine, at the end of 2022, there were no combined antihypertensive drugs in the List of reimbursed drugs. Therefore, there is a need to develop scientific and practical approaches to improve the «Affordable Medicines» reimbursement program in accordance with modern trends in the treatment of hypertension. The aim of the study is to formulate scientific and practical proposals for the inclusion of combined antihypertensive drugs in the state reimbursement program «Affordable Medicines» and to improve external reference pricing. Оbjects of the study were Orders of the Ministry of Health of Ukraine, national and international clinical guidelines, WHO ATC/DDD methodology guidelines. The study used content analysis, methods of comparative and logical analysis. At the 1st stage of the study, it was found that the current legislation of Ukraine does not prohibit the inclusion of combined antihypertensive drugs in the National List of Essential Medicines, and it is not limited solely to WHO recommendations. In the second stage of the study, it is proposed to use the data of pharmacoepidemiological studies and data of studies of actual consumption of combinated antihypertensive drugs in Ukraine, for further state HTA assessment and inclusion in the National List of Essential Medicines and «Affordable Medicines» program. The third and fourth stages of the study showed that the mechanism of external reference pricing needs to be improved and an algorithm for conducting external reference pricing for combined antihypertensive drugs, consisting of five consecutive stages, was developed and proposed. The current regulatory framework of Ukraine provides the possibility of including combined antihypertensive drugs in the state program «Affordable Medicines», and the initiation of the inclusion of medicines is within the competence of the Ministry of Health and the NHSU. A scientific and practical approach to the use of pharmaco-epidemiological research data to identify the most used doses of combined antihypertensive drugs as potential candidates for inclusion in the «Affordable Medicines» program is proposed. A scientific and practical algorithm for external reference pricing for combinated antihypertensive drugs was developed, considering current regulatory and methodological aspects.